Related Experiment Video
Updated: Mar 24, 2026

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I
Afroza Sultana1, Blake J Cochran1, Fatiha Tabet1
1Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Australia, Sydney, New South Wales, Australia; and.
Abstract:
Activation of inflammatory signaling pathways links obesity with metabolic disorders. TLR4-mediated activation of MAPKs and NF-κB are 2 such pathways implicated in obesity-induced inflammation. Apolipoprotein A-I (apoA-I) exerts anti-inflammatory effects on adipocytes by effluxing cholesterol from the cells via the ATP binding cassette transporter A1 (ABCA1). It is not known if these effects involve inhibition of inflammatory signaling pathways by apoA-I. This study asks if apoA-I inhibits activation of MAPKs and NF-κB in mouse 3T3-L1 adipocytes and whether this inhibition is ABCA1 dependent. Incubation of differentiated 3T3-L1 adipocytes with apoA-I decreased cell surface expression of TLR4 by 16 ± 2% and synthesis of the TLR4 adaptor protein, myeloid differentiation primary response 88, by 24 ± 4% in an ABCA1-dependent manner. ApoA-I also inhibited downstream activation of MAPKs, such as ERK, p38MAPK, and JNK, as well as expression of proinflammatory adipokines in bacterial LPS-stimulated 3T3-L1 adipocytes in an ABCA1-dependent manner. ApoA-I, by contrast, suppressed nuclear localization of the p65 subunit of NF-κB by 30 ± 3% in LPS-stimulated 3T3-L1 adipocytes in an ABCA1-independent manner. In conclusion, apoA-I inhibits TLR4-mediated inflammatory signaling pathways in adipocytes by preventing MAPK and NF-κB activation.-Sultana, A., Cochran, B. J., Tabet, F., Patel, M., Cuesta Torres, L., Barter, P. J., Rye, K.-A. Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I.
Insights
Apolipoprotein A-I (apoA-I) inhibits inflammatory signaling in adipocytes by blocking Toll-like receptor 4 (TLR4) activation of MAPKs and NF-κB, offering potential therapeutic strategies for obesity-related metabolic disorders.
Area of Science:
- Molecular Biology
- Cell Biology
- Metabolic Research
Background:
- Obesity is linked to metabolic disorders through inflammatory signaling pathways.
- Toll-like receptor 4 (TLR4)-mediated activation of MAPKs and NF-κB are key inflammatory pathways in obesity.
- Apolipoprotein A-I (apoA-I) has anti-inflammatory effects on adipocytes, but its impact on these specific signaling pathways is unclear.
Purpose of the Study:
- To investigate if apoA-I inhibits MAPKs and NF-κB activation in mouse 3T3-L1 adipocytes.
- To determine if apoA-I's inhibitory effects are dependent on the ATP binding cassette transporter A1 (ABCA1).
Main Methods:
- Differentiated 3T3-L1 adipocytes were incubated with apoA-I.
- Cell surface expression of TLR4 and myeloid differentiation primary response 88 (MyD88) were measured.
- Activation of MAPKs (ERK, p38MAPK, JNK) and NF-κB (p65 subunit nuclear localization) were assessed in lipopolysaccharide (LPS)-stimulated cells.
Main Results:
- ApoA-I decreased TLR4 and MyD88 expression in an ABCA1-dependent manner.
- ApoA-I inhibited MAPK activation and pro-inflammatory adipokine expression, dependent on ABCA1.
- ApoA-I suppressed NF-κB nuclear localization independently of ABCA1.
Conclusions:
- Apolipoprotein A-I inhibits TLR4-mediated inflammatory signaling pathways in adipocytes.
- This inhibition involves preventing MAPK activation and, independently, NF-κB activation.
- The findings suggest apoA-I's potential role in mitigating obesity-induced inflammation.
Related Concept Videos
Inflammation
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
Atherosclerosis III: Management

